<p class="Default"><span style="font-size:14.0pt">143 Oxfam Briefing Paper 2
February 2011 </span></p>

<p class="Default"><b><span style="font-size:30.0pt">Eye on the Ball </span></b><span style="font-size:22.0pt">Medicine regulation – not IP enforcement – can best
deliver quality medicines </span><span style="font-size:18.0pt"><a href="http://www.oxfam.org">www.oxfam.org</a> </span></p>

<p class="Default"><span style="font-size:18.0pt"><span style="mso-spacerun:yes"> </span></span><span style="font-size:8.0pt">An AIDS
patient holding drugs provided through the Thai government treatment programme.
</span></p>

<p class="Default"><span style="font-size:8.0pt">©Tom Greenwood/Oxfam. </span></p>

<p class="MsoNormal"><b><span style="font-size:11.0pt">Poor-quality, or
‘substandard’, medicines threaten patients and public health in developing
countries. Prioritization of medicines regulation by developing-country
governments, with the technical and financial support of rich countries, is
badly needed. Under the guise of helping to address dangerous and ineffective
medicines, rich countries are pushing for new intellectual-property rules and
reliance on police – rather than health regulatory – action. This approach will
not ensure that medicines consistently meet quality standards. Worse, new
intellectual property rules can undermine access to affordable generic
medicines and damage public health. Developing countries must improve medicines
regulation – not expand intellectual-property enforcement – in order to ensure
medicine quality.</span></b></p>

<p class="MsoNormal"><b><span style="font-size:11.0pt"> </span></b></p>

<p class="MsoNormal"><b><span style="font-size:11.0pt"> </span></b></p>

<p class="MsoNormal"><span class="apple-style-span"><span style="font-size:6.5pt;
font-family:Arial;color:black"><a href="https://mail.google.com/mail/?ui=2&ik=628fd2450c&view=att&th=12df9c03def3b437&attid=0.2&disp=attd&zw" target="_blank"><span style="color:#0000CC;text-decoration:none;text-underline:
none"><span style="mso-ignore:vglayout"><img border="0" width="16" height="16" src="file:///C:\Users\Aviva\AppData\Local\Temp\msohtml1\01\clip_image001.gif" style="border-style:initial;border-color:initial;border-bottom-width:0px;
border-left-width:0px;border-right-width:0px;border-top-width:0px;float:left;
height:16px;width:16px" alt="BP143-Eye-on-the-Ball-Medicine-Regulation-020211-en.pdf" class="hu"></span></span></a><b></b></span><b>BP143-Eye-on-the-Ball-Medicine-Regulation-020211-en.pdf</b></span><span style="font-size:6.5pt;font-family:Arial;color:black"><br>

<span class="apple-style-span">502K  </span><span class="apple-converted-space"> </span><span class="apple-style-span"><a href="https://mail.google.com/mail/?ui=2&ik=628fd2450c&view=gvatt&th=12df9c03def3b437&attid=0.2&disp=attd&mime=application/pdf&zw" target="_blank"><span id=":yj"><span style="color:#0000CC">View</span></span></a>  </span><span class="apple-converted-space"> </span><span class="apple-style-span"><a href="https://mail.google.com/mail/?ui=2&ik=628fd2450c&view=att&th=12df9c03def3b437&attid=0.2&disp=attd&zw"><span style="color:#0000CC">Download</span></a>  </span><a href="https://mail.google.com/mail/?ui=2&ik=628fd2450c&view=att&th=12df9c03def3b437&attid=0.2&disp=attd&zw" target="_blank"></a></span><a href="https://mail.google.com/mail/?ui=2&ik=628fd2450c&view=att&th=12df9c03def3b437&attid=0.2&disp=attd&zw" target="_blank"><span style="color:#0000CC;text-decoration:none;
text-underline:none"><span style="mso-ignore:vglayout"><img border="0" width="16" height="16" src="file:///C:\Users\Aviva\AppData\Local\Temp\msohtml1\01\clip_image001.gif" style="border-style:initial;border-color:initial;border-bottom-width:0px;
border-left-width:0px;border-right-width:0px;border-top-width:0px;float:left;
height:16px;width:16px" alt="BP143-Eye-on-the-Ball-Medicine-Regulation-020211-en.pdf" class="hu"></span></span></a><b>BP143-Eye-on-the-Ball-Medicine-Regulation-020211-en.pdf</b><br style="mso-special-character:line-break">

<br style="mso-special-character:line-break">
</p>